Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study (clinicaltrials.gov) - Oct 28, 2026 - P2 | N=46 | Recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New P2 trial • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • BRAF
|